Evidence map›Paper›PMID 41742404›Full record

ArticleCell reports. Medicine2026

Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies.

Jenna S Powers, Katherine M Bricker-Holt, Brianna Williams, Veronica Obregon-Perko, Dormarie E Rivera Rodriguez, Sophia Sukkestad, Lakshita Lopez Lopez, Amir Dashti, Kaleaha Davis, Vinh Dinh and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Jenna S PowersDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Katherine M Bricker-HoltDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Brianna WilliamsDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Veronica Obregon-PerkoDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Dormarie E Rivera RodriguezDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Sophia SukkestadDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Lakshita Lopez LopezDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Amir DashtiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Kaleaha DavisDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Vinh DinhDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Jairo A FonsecaDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
George CotsonisDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA; Center for AIDS Research, Emory University, Atlanta, GA 30322, USA.
Kirk A EasleyDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA; Center for AIDS Research, Emory University, Atlanta, GA 30322, USA.
Kate S LevineDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Lindsay R McManusDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Ross BlancDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Ashley HeimannVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, USA.
Renguang DuVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, USA.
Ryan McNamaraDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Christine M FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Rosemarie D MasonVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, USA.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, USA.
Ann ChahroudiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Center for AIDS Research, Emory University, Atlanta, GA 30322, USA; Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA. Electronic address: ann.m.chahroudi@emory.edu.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
SPF Breeding Colonies at the Yerkes NPRCU24OD011023 · OD · EMORY UNIVERSITY · PI COHEN, JOYCE KIMBERLY · 2012 to 2017
$8.2M
Immune interventions in SIV-infected ART-suppressed infant macaquesR01AI133706 · NIAID · EMORY UNIVERSITY · PI CHAHROUDI, ANN M · 2017 to 2021
$4.1M
Emory Training Program in Translational Research to End the HIV EpidemicT32AI157855 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2021 to 2026
$2.8M
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI133706NIAID NIH HHS T32 AI157855NIAID NIH HHS UM1 AI164566NIH HHS P51 OD011132NIH HHS U24 OD011023
6 · The paper itself

Abstract

Interventions to prevent HIV rebound in the absence of antiretroviral therapy (ART) are needed. Here, we use a rhesus macaque model of pediatric HIV to assess the impact of simian immunodeficiency virus (SIV) Env-specific rhesus monoclonal antibodies (RhmAbs) on viral rebound. We find that RhmAb-treated infants experience delayed rebound compared to controls (median of 64 versus 7.5 days, p = 0.0007). Time to rebound very strongly correlates with both ITS102.01-LS concentrations (r = 0.9, p = 0.002) and anti-drug antibodies against ITS103.01-LS (r = -0.95, p = 0.008). SIVgag-specific CD8

Indexed as

Antibodies, NeutralizingAnti-Retroviral AgentsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAntibodies, MonoclonalCD8-Positive T-LymphocytesHumansMacaca mulattaViral LoadViremiaAntibodies, MonoclonalAntibodies, NeutralizingAnti-Retroviral AgentsART interruptionCD8+ T cellsHIVinfantsneutralizing antibodiesperinatalSIVviral control

Identifiers

PMID41742404
PMCPMC13006440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.